Downloads: 1
158 lines (157 with data), 5.1 kB
T1 Age 17 28 57-year-old T2 Sex 29 34 woman T3 Sign_symptom 69 73 mass E1 Sign_symptom:T3 T4 Lab_value 51 68 rapidly enlarging R1 MODIFY Arg1:T4 Arg2:E1 T5 Biological_structure 81 102 left side of her neck R2 MODIFY Arg1:T5 Arg2:E1 T6 Date 106 110 2010 E2 Date:T6 T7 Therapeutic_procedure 134 147 thyroidectomy E3 Therapeutic_procedure:T7 T8 Detailed_description 128 133 total R3 MODIFY Arg1:T8 Arg2:E3 T9 Therapeutic_procedure 165 175 dissection E4 Therapeutic_procedure:T9 T10 Biological_structure 152 164 central neck R4 MODIFY Arg1:T10 Arg2:E4 T11 Distance 194 200 3.8-cm T12 Disease_disorder 212 226 thyroid cancer E5 Disease_disorder:T12 T13 Detailed_description 201 211 anaplastic R5 MODIFY Arg1:T13 Arg2:E5 R6 MODIFY Arg1:T11 Arg2:E5 T14 Disease_disorder 300 314 thyroid cancer E6 Disease_disorder:T14 T15 Detailed_description 278 299 poorly differentiated R7 MODIFY Arg1:T15 Arg2:E6 T16 Detailed_description 257 274 oncocytic variant R8 MODIFY Arg1:T16 Arg2:E6 T17 Sign_symptom 485 493 involved E7 Sign_symptom:T17 T18 Biological_structure 468 479 lymph nodes T19 Lab_value 460 467 3 of 12 R9 MODIFY Arg1:T19 Arg2:T18 R10 MODIFY Arg1:T18 Arg2:E7 T20 Diagnostic_procedure 423 440 Resection margins E8 Diagnostic_procedure:T20 T21 Lab_value 446 454 positive #1 AnnotatorNotes T21 positive for cancer cells, specifically R11 MODIFY Arg1:T21 Arg2:E8 T22 Date 498 511 3 weeks after E9 Date:T22 T23 Diagnostic_procedure 531 544 thyroglobulin E10 Diagnostic_procedure:T23 T24 Detailed_description 525 530 serum R12 MODIFY Arg1:T24 Arg2:E10 T25 Lab_value 555 577 17.2 ng per milliliter R13 MODIFY Arg1:T25 Arg2:E10 T26 Diagnostic_procedure 597 621 thyroglobulin antibodies E11 Diagnostic_procedure:T26 T27 Lab_value 584 596 undetectable R14 MODIFY Arg1:T27 Arg2:E11 T28 Therapeutic_procedure 655 672 radiation therapy E12 Therapeutic_procedure:T28 T29 Medication 684 695 carboplatin E13 Medication:T29 T30 Medication 700 710 paclitaxel E14 Medication:T30 T31 Medication 711 723 chemotherapy E15 Medication:T31 R15 SUB_PROCEDURE Arg1:E14 Arg2:E15 R16 SUB_PROCEDURE Arg1:E13 Arg2:E15 T32 Diagnostic_procedure 735 748 thyroglobulin E16 Diagnostic_procedure:T32 T33 Detailed_description 729 734 serum R17 MODIFY Arg1:T33 Arg2:E16 T34 Date 758 771 4 weeks after E17 Date:T34 T35 Lab_value 829 851 12.0 ng per milliliter R18 MODIFY Arg1:T35 Arg2:E16 T36 Diagnostic_procedure 863 868 scans E18 Diagnostic_procedure:T36 T37 Date 878 892 3 months later E19 Date:T37 T38 Sign_symptom 927 931 mass E20 Sign_symptom:T38 T39 Biological_structure 909 926 right-sided hilar R19 MODIFY Arg1:T39 Arg2:E20 T40 Medication 998 1008 everolimus E21 Medication:T40 T41 Dosage 1046 1057 10 mg daily R20 MODIFY Arg1:T41 Arg2:E21 T42 Date 1059 1074 Within 6 months E22 Date:T42 T43 Diagnostic_procedure 1086 1091 scans E23 Diagnostic_procedure:T43 T44 Clinical_event 1076 1085 follow-up E24 Clinical_event:T44 T45 Coreference 1108 1114 lesion E25 Coreference:T45 R21 IDENTICAL Arg1:E25 Arg2:E20 T46 Sign_symptom 1127 1145 diminished in size E26 Sign_symptom:T46 R22 MODIFY Arg1:E25 Arg2:E26 T47 Area 1152 1165 3.0 by 2.6 cm T48 Area 1169 1182 1.1 by 0.8 cm R23 MODIFY Arg1:T47 Arg2:E26 R24 MODIFY Arg1:T48 Arg2:E26 T49 Duration 1200 1209 18 months E27 Duration:T49 T50 Sign_symptom 1225 1233 response E28 Sign_symptom:T50 T51 Medication 1237 1247 everolimus E29 Medication:T51 T52 Diagnostic_procedure 1249 1254 scans E30 Diagnostic_procedure:T52 T53 Disease_disorder 1264 1283 progressive disease E31 Disease_disorder:T53 T54 Diagnostic_procedure 1318 1333 mediastinoscopy E32 Diagnostic_procedure:T54 T55 Therapeutic_procedure 1339 1346 removal E33 Therapeutic_procedure:T55 T56 Sign_symptom 1353 1361 enlarged E34 Sign_symptom:T56 T57 Biological_structure 1362 1372 lymph node R25 MODIFY Arg1:T57 Arg2:E34 R26 MODIFY Arg1:T57 Arg2:E33 T58 Disease_disorder 1412 1426 thyroid cancer E35 Disease_disorder:T58 T59 Detailed_description 1401 1411 anaplastic T60 Detailed_description 1390 1400 metastatic R27 MODIFY Arg1:T60 Arg2:E35 R28 MODIFY Arg1:T59 Arg2:E35 T61 Diagnostic_procedure 1489 1499 sequencing E36 Diagnostic_procedure:T61 T62 Detailed_description 1477 1488 Whole-exome R29 MODIFY Arg1:T62 Arg2:E36 T63 Diagnostic_procedure 1517 1523 biopsy E37 Diagnostic_procedure:T63 T64 Detailed_description 1539 1572 pretreatment and resistant tumors R30 MODIFY Arg1:T64 Arg2:E37 T65 Detailed_description 1589 1601 blood sample R31 MODIFY Arg1:T65 Arg2:E37 * OVERLAP E1 E2 R32 BEFORE Arg1:E2 Arg2:E3 * OVERLAP E3 E4 E5 E6 R33 BEFORE Arg1:E6 Arg2:E8 * OVERLAP E8 E7 R34 BEFORE Arg1:E7 Arg2:E9 * OVERLAP E9 E10 E11 R35 BEFORE Arg1:E11 Arg2:E12 * OVERLAP E12 E15 R36 BEFORE Arg1:E15 Arg2:E16 * OVERLAP E16 E17 R37 BEFORE Arg1:E17 Arg2:E18 * OVERLAP E18 E19 E20 E38 E21 T66 Clinical_event 980 994 clinical trial E38 Clinical_event:T66 T67 Detailed_description 972 979 phase 2 R38 MODIFY Arg1:T67 Arg2:E38 R39 BEFORE Arg1:E21 Arg2:E22 * OVERLAP E22 E24 E23 E25 E26 R40 BEFORE Arg1:E26 Arg2:E27 * OVERLAP E27 E28 E29 R41 BEFORE Arg1:E29 Arg2:E30 * OVERLAP E30 E31 E32 E33 E34 E35 E36 E37